Financing
Stock Issuance Proceeds
Neurocrine Biosciences Stock Issuance Proceeds decreased by 36.7% to $23.60M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 26.5%, from $32.10M to $23.60M. Over 4 years (FY 2021 to FY 2025), Stock Issuance Proceeds shows an upward trend with a 47.3% CAGR.
Analysis
StatementCash Flow Statement
SectionFinancing
CategoryCapital Allocation
SignalContext dependent
VolatilityStable
First reportedQ1 2013
Last reportedQ1 2026May 5, 2026
How to read this metric
Higher proceeds often correlate with employee participation in stock-based compensation programs rather than external capital raising.
Detailed definition
Cash inflows resulting from the issuance of common stock, typically through employee stock option exercises or equity co...
Peer comparison
Standard for large-cap companies with significant equity-based compensation programs.
Metric ID:
proceeds_from_stock_issuanceHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $3.00M | $7.50M | $1.80M | $6.10M | $2.60M | $11.40M | $24.60M | $8.20M | $2.90M | $18.80M | $35.40M | $69.90M | $15.80M | $26.40M | $10.00M | $32.10M | $14.40M | $45.60M | $37.30M | $23.60M |
| QoQ Change | — | +150.0% | -76.0% | +238.9% | -57.4% | +338.5% | +115.8% | -66.7% | -64.6% | +548.3% | +88.3% | +97.5% | -77.4% | +67.1% | -62.1% | +221.0% | -55.1% | +216.7% | -18.2% | -36.7% |
| YoY Change | — | — | — | — | -13.3% | +52.0% | >999% | +34.4% | +11.5% | +64.9% | +43.9% | +752.4% | +444.8% | +40.4% | -71.8% | -54.1% | -8.9% | +72.7% | +273.0% | -26.5% |
Range$1.80M – $69.90M
CAGR+54.4%
Avg YoY Growth+180.1%
Median YoY Growth+42.2%
Current Streak2 quarters decline
Stock Issuance Proceeds at Other Companies
Frequently Asked Questions
- What is Neurocrine Biosciences's stock issuance proceeds?
- Neurocrine Biosciences (NBIX) reported stock issuance proceeds of $23.60M in Q1 2026.
- How has Neurocrine Biosciences's stock issuance proceeds changed year-over-year?
- Neurocrine Biosciences's stock issuance proceeds decreased by 26.5% year-over-year, from $32.10M to $23.60M.
- What is the long-term trend for Neurocrine Biosciences's stock issuance proceeds?
- Over 4 years (2021 to 2025), Neurocrine Biosciences's stock issuance proceeds has grown at a 47.3% compound annual growth rate (CAGR), from $27.50M to $129.40M.
- What does stock issuance proceeds mean?
- Cash received from the sale or issuance of company stock.